FindTrial
Sign In

Alternate Day Buprenorphine Administration, Phase IX - 14

Alternate Day Buprenorphine Administration, Phase IX

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00000232
Enrollment
0
Registered
1999-09-21
Start date
1992-03-31
Completion date
Unknown
Last updated
2016-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid-Related Disorders

Brief summary

The purpose of this study is to determine if four times a subjects' daily maintenance dose will hold for 120 hours without changes in agonist and antagonist effects.

Interventions

DRUGBuprenorphine

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
University of Vermont
Lead SponsorOTHER

Study design

Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
22 Years to 51 Years
Healthy volunteers
No

Inclusion criteria

Please contact site for information.

Design outcomes

Primary

MeasureTime frame
Drug use—
Opioid withdrawal—
Opioid agonist effects—
Dose identification—
Pupil diameter—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026